LIQUID biopsy has shown the potential to dramatically speed up and improve the diagnosis of Epstein–Barr virus (EBV)-positive Burkitt’s lymphoma in resource-limited settings, according to a major new study involving patients in sub-Saharan Africa.
Burkitt’s lymphoma, a highly aggressive cancer that predominantly affects children in endemic regions, requires rapid diagnosis to enable timely treatment. However, limited pathology infrastructure across many African healthcare systems often results in significant delays. This study addressed a critical unmet need by evaluating whether a blood-based liquid biopsy approach could offer a faster and accurate alternative to traditional diagnostic pathways.
Fast, Accurate Diagnosis of Burkitt’s Lymphoma
Researchers analysed 377 children and young adults with suspected lymphoma across four hospitals in Tanzania and Uganda. Using clinical features and circulating tumour DNA markers, including MYC mutations, MYC–immunoglobulin translocations, and EBV fragmentomics, the team developed predictive models for diagnosis.
The best-performing liquid biopsy model demonstrated strong diagnostic performance, achieving an area under the curve of 0.95 (95% confidence interval: 0.901–0.981), with sensitivity of 0.86 and specificity of 0.95. These findings were further validated in a prospective cohort, where accuracy remained high (area under the curve: 0.98; 95% confidence interval: 0.942–1.000).
Crucially, liquid biopsy was the only diagnostic result available at multidisciplinary review in 42% of cases, highlighting its practical clinical value. The approach also significantly reduced the median turnaround time from 46.8 days to just 6.5 days (P=4.42×10−10), offering a substantial improvement in diagnostic efficiency.
Implications for Burkitt’s Lymphoma Care
The findings suggest that liquid biopsy could transform diagnostic pathways for Burkitt’s lymphoma in endemic regions, where delays in tissue-based diagnosis often hinder treatment initiation. By providing rapid and reliable molecular results, this approach may help clinicians make earlier decisions and improve patient outcomes.
Overall, liquid biopsy represents a promising tool to address diagnostic inequities in oncology care, particularly in low-resource settings. Future work will be needed to scale this approach and evaluate its impact on survival outcomes in real-world clinical practice. Broader implementation will also require infrastructure for molecular testing, as well as cost considerations and training.
Reference
Chamba C et al. Liquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas. Nat Med. 2026; DOI:10.1038/s41591-026-04291-z.
Featured image: canvasoflight on Adobe Stock
